ABSCI CORP Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
ABSCI CORP (ABSI) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 4.40% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-24.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2026-03-24
- ABSCI CORP share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2025-09-30 was 4.00%, a 9.09% decline year-over-year.
- ABSCI CORP share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2025-06-30 was 4.10%, a 10.87% decline year-over-year.
- ABSCI CORP share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2025-03-31 was 4.40%, a 7.32% increase year-over-year.
- ABSCI CORP share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2024-09-30 was 4.40%, a 2.33% increase year-over-year.
- ABSCI CORP share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2025 was 4.40%, a 4.35% decline from fiscal 2024.
- ABSCI CORP share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2024 was 4.60%, a 2.13% decline from fiscal 2023.
- ABSCI CORP share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2023 was 4.70%, a 11.90% increase from fiscal 2022.
- ABSCI CORP share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2022 was 4.20%, a 180.00% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|---|---|---|
| 2025-12-31 | 4.40% 10-K · filed 2026-03-24 | |||
| 2025-09-30 | 4.00% 10-Q · filed 2025-11-12 | 4.40% 10-Q · filed 2025-11-12 | ||
| 2025-06-30 | 4.10% 10-Q · filed 2025-08-12 | 4.40% 10-Q · filed 2025-08-12 | ||
| 2025-03-31 | 4.40% 10-Q · filed 2025-05-13 | |||
| 2024-12-31 | 4.60% 10-K · filed 2026-03-24 | |||
| 2024-09-30 | 4.40% 10-Q · filed 2025-11-12 | 4.60% 10-Q · filed 2025-11-12 | ||
| 2024-06-30 | 4.60% 10-Q · filed 2025-08-12 | 4.60% 10-Q · filed 2025-08-12 | ||
| 2024-03-31 | 4.10% 10-Q · filed 2025-05-13 | |||
| 2023-12-31 | 4.70% 10-K · filed 2025-03-18 | |||
| 2023-09-30 | 4.30% 10-Q · filed 2024-11-12 | 4.30% 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | 4.00% 10-Q · filed 2024-08-14 | 4.20% 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | 4.20% 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | 4.20% 10-K · filed 2024-03-21 | |||
| 2022-09-30 | 3.30% 10-Q · filed 2023-11-14 | 3.30% 10-Q · filed 2023-11-14 | ||
| 2022-06-30 | 3.00% 10-Q · filed 2023-08-14 | 3.00% 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | 2.20% 10-Q · filed 2023-05-15 | |||
| 2021-12-31 | 1.50% 10-K · filed 2023-03-30 | |||
| 2021-09-30 | 1.10% 10-Q · filed 2022-11-09 | 1.30% 10-Q · filed 2022-11-09 | ||
| 2021-06-30 | 1.30% 10-Q · filed 2022-08-11 | 1.30% 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | 1.30% 10-Q · filed 2022-05-11 | |||
| 2020-12-31 | 1.60% 10-K · filed 2022-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |